ANGLE plc (ANPCY: OTCQX International) | Angle PLC Announces Analysis of CTC-DNA and ctDNA using Illumina assay
ANGLE PLC Breakthrough in Cancer ResearchKey Research Findings
- Successful dual analysis of Circulating Tumor Cells (CTCs) and Circulating Tumor DNA (ctDNA) using Illumina assay
- Study conducted on 27 lung cancer patients
- Used Parsortix® system and Illumina’s 79 gene lung cancer panel
Significant Discoveries
- Untreated patients (n=8): 100% had cancer mutations in CTC-DNA not found in ctDNA
- Treatment-receiving patients (n=19): 90% had unique CTC-DNA mutations
- Dual analysis revealed twice as many potential biomarkers
Upcoming Event
- EACR-Illumina Webinar on February 6, 2025, at 16:00 GMT
- Presenting comprehensive research on CTC and ctDNA analysis
Strategic Collaboration
- ANGLE and Illumina exploring future integration of Parsortix system with NGS instruments
- Potential for multiomics analysis using intact cancer cells
Company Perspective
- Aims to expand liquid biopsy research capabilities
- Provides minimally invasive, repeatable cancer cell sampling
- Potential to offer more comprehensive cancer patient profiling
Webinar Registration
Available at: www.eacr.org/meeting/illumina-webinar-feb25
Source link
#ANGLE #plc #ANPCY #OTCQX #International #Angle #PLC #Announces #Analysis #CTCDNA #ctDNA #Illumina #assay
PressAlchemy helps businesses of all size from startups to established companies to turn their news into headlines. Whether you’re announcing a corporate update, sharing a major project milestone, or launching a new product, press release distribution ensures your story reaches the right audience on top platforms. If you own a business or have a story to share, now’s the time to get noticed.
Expand your reach to 900+ Media Networks, 13.3k Journalists, and a global audience of over a billion users! Get your Press Release or Article featured for your business or story – CLICK HERE.
